Compare Celestica Inc (CLS) vs KKR & Co Inc (KKR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Celestica Inc vs KKR & Co Inc — how do they compare? Celestica Inc trades at $335.66 (market cap $39.16B), while KKR & Co Inc trades at $111.19 (market cap $99.61B). The key difference: KKR & Co Inc is far larger — about 2.5× Celestica Inc's market cap, and KKR & Co Inc pays a 0.7% dividend while Celestica Inc pays none. Which is the better fit depends on your goals.
| CLS | KKR | |
|---|---|---|
Market Cap | $39.16B | $99.61B |
Sector | Technology | Financials |
52-Week High | $472.40 | $149.34 |
52-Week Low | $181.34 | $83.88 |
Enterprise Value | $39.44B | $22.17B |
Dividend Yield | — | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CLS trades at $336.97, up 7.11% on the day, with a bearish technical signal from moving averages but strong fundamental performance. The company reported three consecutive quarterly EPS beats, with Q2 2026 actual EPS of $2.54 exceeding the $2.29 estimate. Revenue for 2025 was $12.39 billion, with a net income margin of 7.16% and robust ROE of 52.69%. Recent news highlights a $3 billion equity offering to fund AI infrastructure growth, alongside new contracts with key tech partners.
The outlook is supported by accelerating AI-driven demand and raised guidance, but near-term dilution from the equity raise poses a risk. Analyst consensus is strongly bullish with a $466.50 price target, though the stock's premium valuation requires careful monitoring of execution against growth expectations.
KKR's stock trades at $110.37, up 6.3% today, showing strong momentum near recent highs. The technical outlook is bullish with the price above key moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $1.63, beating estimates of $1.43, with revenue growth supported by recent acquisitions including Integer Holdings and Medicover India. Analyst sentiment remains overwhelmingly positive with 24 buy ratings and a $127.22 consensus price target.
KKR presents a compelling investment case with strong earnings momentum, strategic acquisitions expanding its healthcare and infrastructure portfolios, and robust analyst support. However, risks include execution challenges from recent M&A activity, potential market volatility affecting asset valuations, and the stock's current premium valuation multiples. The company's ability to integrate acquisitions and maintain fundraising momentum will be key drivers of future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Celestica Inc
Celestica provides supply chain and manufacturing solutions for global technology companies. It specializes in high-complexity assembly and platform solutions for AI data centers, aerospace, and medical markets.
Read more on CLS →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
